Form 4: CARGO Therapeutics Director Sells Options Post-Merger

A director of CARGO Therapeutics, Inc. disposed of stock options following the company's acquisition by Concentra Biosciences, LLC.

Summary

• John A. Orwin, a Director of CARGO Therapeutics, Inc. (CRGX), disposed of all his derivative securities (stock options) on August 19, 2025.
• This disposal was a direct result of the Agreement and Plan of Merger dated July 7, 2025, under which Concentra Biosciences, LLC acquired CARGO Therapeutics.
• The acquisition involved a tender offer completed on August 18, 2025, for all outstanding shares of CARGO Therapeutics at an offer price of $4.379 per share in cash plus one non-transferable contractual contingent value right (CVR).
• Outstanding stock options became fully vested and were converted into a cash amount (equal to the excess of the cash offer price over the exercise price, multiplied by the number of underlying shares) and one CVR per underlying share, or canceled for no consideration if the exercise price was equal to or greater than the cash offer price.
• Orwin disposed of 15,865 stock options with an exercise price of $1.09 and 25,000 stock options with an exercise price of $4.35, resulting in zero derivative securities beneficially owned post-transaction.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger and the successful disposition of in-the-money options for a director, indicating a positive liquidity event for shareholders and option holders. The transaction proceeded as planned, reflecting a successful acquisition outcome for the company's equity holders.

Positives

• The completion of the merger provides a clear exit and liquidity event for CARGO Therapeutics' shareholders and option holders.
• Stock options held by the director became fully vested and exercisable, allowing for their conversion into cash and CVRs, indicating a positive financial outcome for the director's in-the-money options.

Negatives

• Options with an exercise price equal to or greater than the cash offer price of $4.379 per share were canceled for no consideration, potentially resulting in a loss for some option holders.
• CARGO Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Concentra Biosciences, LLC.

Future Outlook

This Form 4 filing primarily reports a past transaction related to a completed merger and does not provide forward-looking statements or guidance regarding the future operations or financial performance of the acquired entity or the acquiring company.

Industry Context

This filing reflects a common outcome in the biotechnology or pharmaceutical industry where smaller, innovative companies are acquired by larger entities, often after achieving certain clinical milestones or demonstrating promising pipelines. The use of Contingent Value Rights (CVRs) is also a common mechanism in biotech mergers to bridge valuation gaps based on future clinical, regulatory, or commercial achievements.

Comparison to Industry Standards

• This transaction aligns with typical M&A activity in the biotech sector, where acquisitions often involve a cash component and contingent value rights (CVRs).
• Similar structures have been observed in other biotech acquisitions, such as Bristol Myers Squibb's acquisition of MyoKardia, which also utilized CVRs, or Gilead Sciences' acquisition of Immunomedics.
• The offer price of $4.379 per share, combined with CVRs, reflects a valuation based on CARGO Therapeutics' assets and potential, consistent with how early-stage or clinical-stage biotech companies are valued in M&A transactions.

Stakeholder Impact

• Shareholders: Received $4.379 per share in cash plus one CVR for each share, providing a liquidity event.
• Option Holders: In-the-money options were converted to cash and CVRs, while out-of-the-money options were canceled for no consideration.
• Employees: CARGO Therapeutics, Inc. is now a wholly-owned subsidiary, which may lead to changes in corporate structure or employment terms, though not explicitly detailed in this filing.

Next Steps

• The Issuer (CARGO Therapeutics, Inc.) will continue its operations as a wholly-owned subsidiary of Concentra Biosciences, LLC.
• Holders of Contingent Value Rights (CVRs) will await potential future payments based on the achievement of specific milestones as defined in the CVR Agreement.

Key Dates

Recommendation

The company, CARGO Therapeutics, Inc., has been acquired by Concentra Biosciences, LLC and is no longer publicly traded. Therefore, a traditional stock recommendation (buy/sell/strong buy/strong sell) is not applicable for CRGX shares. For investors who held CRGX shares, the merger provided a cash payout and contingent value rights (CVRs), representing a liquidity event. The CVRs may still hold future value depending on the achievement of specific milestones.

Keywords

CARGO Therapeutics, CRGX, Concentra Biosciences, Merger, Acquisition, Tender Offer, Stock Options, Form 4, Insider Trading, Director Transaction, Contingent Value Right, CVR